430 related articles for article (PubMed ID: 20533506)
41. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
42. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Wright CD; Wain JC; Lynch TJ; Choi NC; Grossbard ML; Carey RW; Moncure AC; Grillo HC; Mathisen DJ
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):811-5; discussion 816. PubMed ID: 9375611
[TBL] [Abstract][Full Text] [Related]
43. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
44. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction.
Posner MC; Gooding WE; Landreneau RJ; Rosenstein MM; Clarke MR; Peterson MS; Lembersky BC
Cancer J Sci Am; 1998; 4(4):237-46. PubMed ID: 9689982
[TBL] [Abstract][Full Text] [Related]
45. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Stahl M; Wilke H; Fink U; Stuschke M; Walz MK; Siewert JR; Molls M; Fett W; Makoski HB; Breuer N; Schmidt U; Niebel W; Sack H; Eigler FW; Seeber S
J Clin Oncol; 1996 Mar; 14(3):829-37. PubMed ID: 8622031
[TBL] [Abstract][Full Text] [Related]
46. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
47. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.
Kleinberg LR; Catalano PJ; Forastiere AA; Keller SM; Mitchel EP; Anne PR; Benson AB
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):738-46. PubMed ID: 26972646
[TBL] [Abstract][Full Text] [Related]
48. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
[TBL] [Abstract][Full Text] [Related]
49. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Gaspar LE; Winter K; Kocha WI; Coia LR; Herskovic A; Graham M
Cancer; 2000 Mar; 88(5):988-95. PubMed ID: 10699886
[TBL] [Abstract][Full Text] [Related]
50. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
[TBL] [Abstract][Full Text] [Related]
51. Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Lew JI; Gooding WE; Ribeiro U; Safatle-Ribeiro AV; Posner MC
Arch Surg; 2001 Jul; 136(7):737-42; discussion 743. PubMed ID: 11448381
[TBL] [Abstract][Full Text] [Related]
52. A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Chang H; Shin SK; Cho BC; Lee CG; Kim CB; Kim DJ; Lee JG; Hur J; Lee CY; Bae MK; Kim HR; Lee SK; Park JC; Lee H; Kim HI; Chung H; Cha J; Lee YC; Kim JH
Cancer Chemother Pharmacol; 2014 Apr; 73(4):665-71. PubMed ID: 24562525
[TBL] [Abstract][Full Text] [Related]
53. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Mason DP; Rodriguez CP; Ives DI
J Thorac Oncol; 2009 Oct; 4(10):1264-9. PubMed ID: 19668013
[TBL] [Abstract][Full Text] [Related]
54. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
[TBL] [Abstract][Full Text] [Related]
55. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Govindan R; McLeod H; Mantravadi P; Fineberg N; Helft P; Kesler K; Hanna N; Stoner C; Ansari R; Fox E
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):18-21. PubMed ID: 15685829
[TBL] [Abstract][Full Text] [Related]
56. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
57. New developments in the treatment of esophageal cancer.
Ilson DH
Clin Adv Hematol Oncol; 2004 Feb; 2(2):97-104. PubMed ID: 16163169
[TBL] [Abstract][Full Text] [Related]
58. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.
Bains MS; Stojadinovic A; Minsky B; Rusch V; Turnbull A; Korst R; Ginsberg R; Kelsen DP; Ilson DH
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):270-7. PubMed ID: 12167786
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
60. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
